Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Amortizatization of Intangibles (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Amortizatization of Intangibles for 15 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Amortizatization of Intangibles fell 78.7% year-over-year to $1.2 million, compared with a TTM value of $1.3 million through Dec 2025, down 83.98%, and an annual FY2025 reading of $5.8 million, up 78.45% over the prior year.
  • Amortizatization of Intangibles was $1.2 million for Q4 2025 at Arrowhead Pharmaceuticals, down from $1.2 million in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $11.1 million in Q3 2024 and bottomed at -$7.0 million in Q2 2024.
  • Average Amortizatization of Intangibles over 5 years is $439350.0, with a median of $165500.0 recorded in 2021.
  • The sharpest move saw Amortizatization of Intangibles crashed 3401.96% in 2022, then skyrocketed 1027.66% in 2024.
  • Year by year, Amortizatization of Intangibles stood at $280000.0 in 2021, then plummeted by 346.43% to -$690000.0 in 2022, then surged by 221.01% to $835000.0 in 2023, then skyrocketed by 583.11% to $5.7 million in 2024, then plummeted by 78.7% to $1.2 million in 2025.
  • Business Quant data shows Amortizatization of Intangibles for ARWR at $1.2 million in Q4 2025, $1.2 million in Q3 2025, and $1.8 million in Q2 2025.